Antibody, Drug Delivery and Gene Therapy - Clinical Research Informer

The Power of Lipids: Enhancing Drug Delivery with Nanoparticles

Roots Analysis

MAY 21, 2024

In addition, NLCs offer benefits such as high drug loading capacity, improved drug retention and avoidance of drug expulsion. Advantages of Lipid Nanoparticle LNPs are gaining significant attention of formulation scientists in drug delivery due to the various advantages offered by them.

Drug Delivery

Drug Delivery Drugs Gene Therapy Bioavailability

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

APRIL 24, 2023

The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drug delivery. Liposomes have the same function as lipid nanoparticles in drug delivery but have a simpler formulation. Lipid nanoparticle drug delivery was in the spotlight during the Covid-19 pandemic.

Drug Delivery

Drug Delivery Vaccination Vaccine Research

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: The company now has clients across big pharma.

Antibody

Antibody Gene Therapy Gene In-Vitro

Evox Therapeutics acquires exosome AAV technology from Codiak

Drug Discovery World

JUNE 22, 2023

This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralising antibodies. “We The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy

Gene Therapy Gene Editing Drug Delivery Gene

The 3rd Annual Blood-Brain Barrier Summit Returns in August 2021

pharmaphorum

APRIL 29, 2021

To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. 3-day Conference | June 28-30, 2021.

Drug Delivery

Drug Delivery Gene Therapy In-Vivo Antibody

Drug discovery’s latest top-level appointments

Drug Discovery World

APRIL 29, 2024

He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021. Carbone brings over 35 years of experience in operations, quality, and technology leadership in biotechnology, pharmaceuticals, and advanced therapies.

Drugs

Drugs Sales Gene Therapy Life Science

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer

Engineer Antibody Protein In-Vivo

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials

Trials Drug Delivery Drugs Gene

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Web: [link].

Manufacturing

Manufacturing Drug Delivery Marketing Drug Delivery Systems

Merck KGaA raises full-year forecast; Perlmutter’s new gig tackles ‘undruggable targets’

The Pharma Data

MAY 5, 2021

New Scottish Agency Would Ensure Supply Of Cost-Effective Drugs ( Pink Sheet ). India approves Roche/Regeneron antibody cocktail to treat COVID-19 ( Reuters ). Adagio offers first peek at Covid-19 antibody data, with preventative numbers that may rival mRNA vaccines ( Endpoints ).

Vaccination

Vaccination Vaccine Gene Therapy Contract Packaging

Biopharmaceutical Excipient Manufacturing Market: Current Scenario and Future Potential

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing

Manufacturing Marketing Contract Manufacturing Protein

FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)

The Pharma Data

MAY 15, 2023

If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 7 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye. Roche’s Chief Medical Officer and Head of Global Product Development. “If

Antibody

Antibody In-Vitro Clinical Development Medicine

FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)

The Pharma Data

JUNE 26, 2021

About Roche in Ophthalmology Roche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies. Faricimab is the first investigational bispecific antibody designed for the eye.

Drug Delivery

Drug Delivery Clinical Trials Clinical Trials Medicine

Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. 1 4 About Vabysmo ® ( faricimab ) Vabysmo is the first bispecific antibody approved for the eye.

Antibody

Antibody In-Vitro Development Trials

Clinical Research Informer

The Power of Lipids: Enhancing Drug Delivery with Nanoparticles

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Trending Sources

Turning science into business: An optimised alternative to antibodies

Evox Therapeutics acquires exosome AAV technology from Codiak

The 3rd Annual Blood-Brain Barrier Summit Returns in August 2021

Drug discovery’s latest top-level appointments

What to expect from PEGS Europe 2023: Day 2

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Merck KGaA raises full-year forecast; Perlmutter’s new gig tackles ‘undruggable targets’

Biopharmaceutical Excipient Manufacturing Market: Current Scenario and Future Potential

FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)

FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)

Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023

Stay Connected